Exiqon Completes $470M Nordic IPO; Will Use Proceeds for US Operations, Dx Development

According to CEO Lars Kongsbak, Exiqon decided to go public to gain additional funding and strengthen its position in the miRNA field where it competes against larger, publicly funded firms like Agilent Technologies and Applied Biosystems.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.